Table 1. Patient characteristics.
MRD, measurable residual disease; FISH, fluorescence in situ hybridization; ELN, European LeukemiaNet.
| Characteristic | Measure |
|---|---|
| Median age, years (range) | 67 (19 to 73) |
| Male/female, no. of patients | 11/4 |
| Median/mean bone marrow blasts, % (range) | 6/21 (0 to 89) |
| Disease history, no. | |
| De novo AML | 10 |
| Secondary or treatment-related AML | 5 |
| Median number of prior therapies, no. (range) | 3 (1 to 8) |
| Prior therapy regimens, no. of patients | |
| Intensive chemotherapy with cytarabine | 14 |
| Hypomethylating agent only | 1 |
| Disease status, no. of patients | |
| Active disease | 10 |
| MRD positive by flow cytometry | 3 |
| MRD positive by FISH | 2 |
| Cytogenetics/FISH, no. of patients | |
| Complex | 8 |
| Isolated trisomy 13 | 1 |
| Isolated trisomy 8 | 1 |
| Isolated del 5q | 1 |
| t(1;17) + del 19 | 1 |
| Normal | 3 |
| Recurrently mutated genes, no. of patients | |
| TP53 | 7 |
| DNMT3A | 6 |
| TET2 | 4 |
| SF3B1 | 3 |
| ASXL1 | 3 |
| CBL | 3 |
| SRSF2 | 2 |
| FLT3 | 2 |
| NRAS | 2 |
| RUNX1 | 2 |
| SUZ12 | 2 |
| 2017 ELN Genetic Risk Stratification, no. of patients | |
| Adverse | 14 |
| Intermediate | 1* |
| Favorable | 0 |
*
NGS genotype not available, classified as intermediate based on normal karyotype.